Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results1

Elevated apoC-III levels predict increased cardiovascular risk when present on LDL and HDL particles. We developed novel high-throughput chemiluminescent ELISAs that capture apoB, lipoprotein (a) [Lp(a)], and apoA-I in plasma and then detect apoC-III on these individual lipoproteins as apoCIII-apoB,...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Xiaohong Yang, Sang-Rok Lee, Yun-Seok Choi, Veronica J. Alexander, Andres Digenio, Qingqing Yang, Yury I. Miller, Joseph L. Witztum, Sotirios Tsimikas
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2016-04-01
Serie:	Journal of Lipid Research
Soggetti:	hypertriglyceridemia triglycerides remnant lipoproteins antisense oligonucleotides cardiovascular disease familial chylomicronemia syndrome
Accesso online:	http://www.sciencedirect.com/science/article/pii/S0022227520354250
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!